Early taxane exposure and neurotoxicity in breast cancer patients.
Humans
Female
Breast Neoplasms
/ drug therapy
Quality of Life
Middle Aged
Prospective Studies
Neurotoxicity Syndromes
/ etiology
Paclitaxel
/ adverse effects
Aged
Peripheral Nervous System Diseases
/ chemically induced
Adult
Taxoids
/ adverse effects
Antineoplastic Agents, Phytogenic
/ adverse effects
Bridged-Ring Compounds
/ adverse effects
Neurotoxicity
Quality of life
Taxane
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
received:
23
04
2024
accepted:
27
09
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
7
10
2024
Statut:
epublish
Résumé
Breast cancer is the most diagnosed tumor and a leading cause of cancer death in women worldwide. Taxanes are the most used chemotherapeutic agents and are strictly connected to neurotoxicity. Taxane-induced neuropathy (TIN) significantly impacts patients' quality of life (QOL). Early identification and management of TIN could improve preventive strategies to preserve patients' QOL during and after breast cancer treatment. This prospective, observational study aimed to evaluate the taxane-induced neuropathy (TIN) in early breast cancer patients treated with weekly paclitaxel at an earlier stage and identify any correlation between TIN and QOL. Data from stage I-III breast cancer patients treated with taxane-based therapy between 2018 and 2022 were collected at the Medical Oncology Unit of the University Hospital of Cagliari. Peripheral neuropathy was evaluated using the NCI-CTCAE scale (National Cancer Institute, Common Terminology Criteria for Adverse Events) at every drug administration. In contrast, QOL was assessed using EORTC QLC-CIPN20 and FACT-Taxane questionnaire at baseline (T0), after 4 weeks (T1) and 12 (T2) weeks of treatment. Statistical analysis was performed to evaluate the correlation between neurotoxicity and QOL. Neurotoxicity incidence peaked at the third, fourth, and sixth week of treatment, with patients reporting grade 1 and 2 neurotoxicity. Simultaneously with increasing doses of paclitaxel, significant differences in QOL were observed in early treatment cycles relating to TIN presentation. Patients with higher neurotoxicity grades reported lower QOL scores. Despite the absence of effective treatments to prevent paclitaxel-induced neurotoxicity, symptoms are managed through dosage reduction, delay, or treatment interruption. Future research should focus on identifying neuroprotective measures to avoid an irreversible decline in the quality of life for breast cancer survivors.
Identifiants
pubmed: 39375221
doi: 10.1007/s00520-024-08908-2
pii: 10.1007/s00520-024-08908-2
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
Taxoids
0
Antineoplastic Agents, Phytogenic
0
taxane
1605-68-1
Bridged-Ring Compounds
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
709Informations de copyright
© 2024. The Author(s).
Références
Global Burden of Disease Cancer Collaboration (2015) The global burden of cancer 2013. JAMA Oncol 1(4):505–527. https://doi.org/10.1001/jamaoncol.2015.0735
doi: 10.1001/jamaoncol.2015.0735
Global Cancer Observatory: Cancer Today. https://gco.iarc.fr/today/home
de Matteis A, Nuzzo F, D’Aiuto G, Labonia V, Landi G, Rossi E, Mastro AA, Botti G, De Maio E, Perrone F (2002) Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 94(4):895–901. https://doi.org/10.1002/cncr.20335.abs
doi: 10.1002/cncr.20335.abs
Foucquier J, Guedj M (2015) Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 3(3):e00149. https://doi.org/10.1002/prp2.149 . Erratum in: Pharmacol Res Perspect. 2019 Dec;7(6):e00549
doi: 10.1002/prp2.149
Anampa J, Makower D, Sparano JA (2015) Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med 17(13):195. https://doi.org/10.1186/s12916-015-0439-8
doi: 10.1186/s12916-015-0439-8
Kang D, Kim S, Kim H, Lee M, Kong SY, Chang YJ, Sim SH, Kim YJ, Cho J (2023) Surveillance of symptom burden using the patient-reported outcome version of the common terminology criteria for adverse events in patients with various types of cancers during chemoradiation therapy: real-world study. JMIR Public Health Surveill 8(9):e44105. https://doi.org/10.2196/44105
doi: 10.2196/44105
Gornstein E, Schwarz TL (2014) The paradox of paclitaxel neurotoxicity: mechanisms and unanswered questions. Neuropharmacology 76 Pt A:175–83. https://doi.org/10.1016/j.neuropharm.2013.08.016
doi: 10.1016/j.neuropharm.2013.08.016
Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lantéri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R, EORTC Quality of Life Group (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–9. https://doi.org/10.1016/j.ejca.2005.02.012
doi: 10.1016/j.ejca.2005.02.012
Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumors: a systematic review of clinical data. Lancet Oncol 6(4):229–239. https://doi.org/10.1016/S1470-2045(05)70094-2
doi: 10.1016/S1470-2045(05)70094-2
da Costa R, Passos GF, Quintão NLM, Fernandes ES, Maia JRLCB, Campos MM, Calixto JB (2020) Taxane-induced neurotoxicity: pathophysiology and therapeutic perspectives. Br J Pharmacol 177(14):3127–3146. https://doi.org/10.1111/bph.15086
doi: 10.1111/bph.15086
Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC (1993) Neurotoxicity of taxol. J Natl Cancer Inst Monogr 15:107–115
Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16(10):3353–3361. https://doi.org/10.1200/JCO.1998.16.10.3353 . Erratum in: J Clin Oncol. 2006 May 10;24(14):2220. Albanel, J [corrected to Albanell, J]
doi: 10.1200/JCO.1998.16.10.3353
Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31(21):2699–2707. https://doi.org/10.1200/JCO.2013.49.1514
doi: 10.1200/JCO.2013.49.1514
Hertz DL (2024) Incidence, description, predictors, and consequences of persistent taxane-induced peripheral neuropathy. Curr Opin Support Palliat Care 18(1):30–38. https://doi.org/10.1097/SPC.0000000000000684.]
doi: 10.1097/SPC.0000000000000684.]
Swain SM, Arezzo JC (2008) Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 6(6):455–467
Seidman AD et al (2004) CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. JCO 22:512–512. https://doi.org/10.1200/jco.2004.22.90140.512
doi: 10.1200/jco.2004.22.90140.512
Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663–1671. https://doi.org/10.1056/NEJMoa0707056 . Erratum in: N Engl J Med. 2008 Jul 3;359(1):106. Erratum in: N Engl J Med. 2009 Apr 16;360(16):1685
doi: 10.1056/NEJMoa0707056
Van Gerven JM, Moll JW, van den Bent MJ, Bontenbal M, van der Burg ME, Verweij J, Vecht CJ (1994) Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 30A(8):1074–1077. https://doi.org/10.1016/0959-8049(94)90459-6
doi: 10.1016/0959-8049(94)90459-6
Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23(24):5542–5551. https://doi.org/10.1200/JCO.2005.02.027
doi: 10.1200/JCO.2005.02.027
Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH (2009) Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17(12):1483–1491. https://doi.org/10.1007/s00520-009-0613-7
doi: 10.1007/s00520-009-0613-7
Schwab L, Visovsky C (2023) Psychological distress and quality of life in breast cancer survivors with taxane-induced peripheral neuropathy: a scoping review. Front Oncol 10(12):1005083. https://doi.org/10.3389/fonc.2022.1005083
doi: 10.3389/fonc.2022.1005083
Eckhoff L, Knoop A, Jensen MB, Ewertz M (2015) Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer 51(3):292–300. https://doi.org/10.1016/j.ejca.2014.11.024
doi: 10.1016/j.ejca.2014.11.024
Bennedsgaard K, Ventzel L, Themistocleous AC, Bennett DL, Jensen AB, Jensen AR, Andersen NT, Jensen TS, Tankisi H, Finnerup NB (2020) Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy. Cancer Med 9(14):5114–5123. https://doi.org/10.1002/cam4.3129
doi: 10.1002/cam4.3129
Engvall K, Gréen H, Fredrikson M, Lagerlund M, Lewin F, Åvall-Lundqvist E (2022) Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study. Breast Cancer Res Treat 195(3):379–391. https://doi.org/10.1007/s10549-022-06670-9
doi: 10.1007/s10549-022-06670-9
Costa-Pereira JT, Serrão P, Martins I, Tavares I (2020) Serotoninergic pain modulation from the rostral ventromedial medulla (RVM) in chemotherapy-induced neuropathy: the role of spinal 5-HT3 receptors. Eur J Neurosci 51(8):1756–1769. https://doi.org/10.1111/ejn.14614
doi: 10.1111/ejn.14614
Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, Alliance for Clinical Trials in Oncology (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359–67. https://doi.org/10.1001/jama.2013.2813
doi: 10.1001/jama.2013.2813
Coffeen U, Sotomayor-Sobrino MA, Jiménez-González A, Balcazar-Ochoa LG, Hernández-Delgado P, Fresán A, Plancarte-Sanchez R, Arias-Muñóz SD, Ochoa-Aguilar A (2019) Chemotherapy-induced neuropathic pain characteristics in Mexico’s National Cancer Center pain clinic. J Pain Res 3(12):1331–1339. https://doi.org/10.2147/JPR.S186107
doi: 10.2147/JPR.S186107
Kawashiri T, Inoue M, Mori K, Kobayashi D, Mine K, Ushio S, Kudamatsu H, Uchida M, Egashira N, Shimazoe T (2021) Preclinical and clinical evidence of therapeutic agents for paclitaxel-induced peripheral neuropathy. Int J Mol Sci 22(16):8733. https://doi.org/10.3390/ijms22168733
doi: 10.3390/ijms22168733
Tanay MAL, Armes J, Moss-Morris R, Rafferty AM, Robert G (2023) A systematic review of behavioural and exercise interventions for the prevention and management of chemotherapy-induced peripheral neuropathy symptoms. J Cancer Surviv 17(1):254–277. https://doi.org/10.1007/s11764-021-00997-w
doi: 10.1007/s11764-021-00997-w